Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women

被引:66
作者
Aiello, EJ
Tworoger, SS
Yasui, Y
Stanczyk, FZ
Potter, J
Ulrich, CM
Irwin, M
McTiernan, A
机构
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA
[2] Univ Washington, Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA 98109 USA
[3] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98109 USA
[4] Univ Washington, Sch Med, Dept Med, Seattle, WA 98109 USA
[5] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
[7] Univ So Calif, Sch Med, Los Angeles, CA 90089 USA
[8] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA
关键词
D O I
10.1158/1055-9965.EPI-04-0920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Hormone therapy use has been positively associated with mammographic density in several studies. However, few studies have examined the association between endogenous hormone levels and mammographic density. Therefore, we evaluated the relationship of endogenous sex hormones, insulin-like growth factor (IGF), and lipids with mammographic density in 88 overweight, postmenopausal women not taking hormone therapy. Methods: Percent density and dense area were evaluated as continuous measures using a computer-assisted program. We used multiple linear regression to evaluate the associations of sex hormones, IGF, and cholesterol with mammographic density, adjusting for confounders, including adiposity. We evaluated stratification by history of hormone therapy use (former versus never) and hormone therapy latency (< 5 versus >= 5 years). Results: Among former hormone therapy users, mammographic density was inversely associated with circulating levels of estrone (P = 0.01), estradiol (P = 0.003), free estradiol (P = 0.004), testosterone (P = 0.04), free testosterone (P = 0.02), androstenedione (P < 0.001), dehydroepiandrosterone (P = 0.01), and the ratio of IGF-I to its binding protein (IGF-I/IGFBP-3; P = 0.04). We found similar associations when we limited the analyses to women who had used hormone therapy within the past 5 years. We also noted positive associations of mammographic density with total cholesterol (P = 0.03) and low-density lipoprotein (P = 0.03) among former hormone therapy users. No associations were noted among women who had never used hormone therapy. Conclusions: These results suggest that there is an inverse relationship between endogenous sex hormones and mammographic density in postmenopausal women among former users of hormone therapy. This is not consistent with the hormone therapy literature and should be confirmed in larger studies.
引用
收藏
页码:1411 / 1417
页数:7
相关论文
共 52 条
[1]   Mammographic density is related to stroma and stromal proteoglycan expression [J].
Alowami, S ;
Troup, S ;
Al-Haddad, S ;
Kirkpatrick, I ;
Watson, PH .
BREAST CANCER RESEARCH, 2003, 5 (05) :R129-R135
[2]   The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women [J].
Annamento-Villareal, RC ;
Napoli, N ;
Klug, T ;
Civitelli, R .
BONE, 2004, 35 (03) :682-688
[3]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[4]  
BOYD NF, 1995, CANCER EPIDEM BIOMAR, V4, P727
[5]   The association of breast mitogens with mammographic densities [J].
Boyd, NF ;
Stone, J ;
Martin, LJ ;
Jong, R ;
Fishel, E ;
Yaffe, M ;
Hammond, G ;
Minkin, S .
BRITISH JOURNAL OF CANCER, 2002, 87 (08) :876-882
[6]   QUANTITATIVE CLASSIFICATION OF MAMMOGRAPHIC DENSITIES AND BREAST-CANCER RISK - RESULTS FROM THE CANADIAN NATIONAL BREAST SCREENING STUDY [J].
BOYD, NF ;
BYNG, JW ;
JONG, RA ;
FISHELL, EK ;
LITTLE, LE ;
MILLER, AB ;
LOCKWOOD, GA ;
TRITCHLER, DL ;
YAFFE, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (09) :670-675
[7]   PLASMA-LIPIDS IN PREMENOPAUSAL WOMEN WITH MAMMOGRAPHIC DYSPLASIA [J].
BOYD, NF ;
MCGUIRE, V ;
FISHELL, E ;
KURIOV, V ;
LOCKWOOD, G ;
TRITCHLER, D .
BRITISH JOURNAL OF CANCER, 1989, 59 (05) :766-771
[8]  
Byng JW, 1997, CANCER, V80, P66, DOI 10.1002/(SICI)1097-0142(19970701)80:1<66::AID-CNCR9>3.0.CO
[9]  
2-D
[10]  
Byrne C, 2000, CANCER RES, V60, P3744